SLGL
Sol-Gel Technologies Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
77.73
▼ 0.77 (0.97%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
81.92
Prev close
78.50
Day high
81.92
Day low
77.17
Volume
33.16K
Market cap
$254.10M
P/E (TTM)
—
52W range
20.06 – 97.97
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.95M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 12, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 951 | $68.00K | Indirect |
| Jul 14, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.70K | $124.82K | Indirect |
| Jul 10, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 529 | $39.04K | Indirect |
| Jul 2, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.71K | $123.22K | Indirect |
| May 20, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.56K | $100.71K | Indirect |
| May 13, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 3.44K | $231.50K | Indirect |
| Mar 24, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 39.66K | $2.86M | Indirect |
| Feb 13, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 291 | $18.33K | Indirect |
| Feb 2, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 100 | $5.80K | Indirect |
| Feb 2, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 100 | $5.80K | Indirect |
| Jan 27, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 100 | $5.71K | Indirect |
| Jan 23, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 3.32K | $187.36K | Indirect |
| Jan 5, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.59K | $108.86K | Indirect |
| Dec 31, 25 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 66.30K | $2.78M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
OPALEYE MANAGEMENT, INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-8.22%
-6.9%
1M
-3.50%
-7.2%
3M
+13.79%
+10.7%
6M
-7.44%
-18.5%
YTD
+84.46%
+72.2%
1Y
+322.45%
+302.4%
3Y
+186.83%
+112.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$254.10M
Enterprise value$207.33M
Revenue (TTM)$1.79M
Gross profit$-21.01M
EBITDA$-17.69M
Net income$-16.34M
EPS (TTM)$-5.62
Free cash flow$-2.24M
Total cash$47.93M
Total debt$770.00K
Book value / share$14.69
Shares outstanding3.27M
Float529.93K
Short % of float5.08%
Dividend yield—
Beta (5Y)—
Short interest
Shares short
53.55K
Prior 47.50K
Change vs prior
+12.7%
Shorts adding
% of float
5.08%
Normal
% of shares out
1.64%
Against total outstanding
Days to cover
1.3
Liquid
Float
529.93K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-10.09
PEG ratio—
Price / sales—
Price / book5.29
EV / revenue115.50
EV / EBITDA-11.72
Gross margin0.00%
Operating margin-704.23%
Profit margin0.00%
Return on equity-40.85%
Return on assets-23.87%
Debt / equity1.60
Current ratio10.37
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $19.39M | $11.54M | $1.55M | $3.88M | — | +68.0% |
| Operating revenue | $19.39M | $11.54M | $1.55M | $3.88M | — | +68.0% |
| Research & development | $22.80M | $17.80M | $23.54M | $12.68M | — | +28.1% |
| Selling, general & admin | $4.18M | $5.75M | $7.37M | $7.45M | — | -27.4% |
| Total operating expense | $26.93M | $23.55M | $30.86M | $20.13M | — | +14.3% |
| Operating income | -$7.54M | -$12.01M | -$29.30M | -$16.24M | — | +37.3% |
| Net interest income | $1.41M | $1.43M | $2.07M | $1.32M | — | -1.6% |
| Pre-tax income | -$6.13M | -$10.58M | -$27.24M | -$14.92M | — | +42.1% |
| Tax provision | — | — | — | — | $0 | — |
| Net income | -$6.13M | -$10.58M | -$27.24M | -$14.92M | — | +42.1% |
| Net income to common | -$6.13M | -$10.58M | -$27.24M | -$14.92M | — | +42.1% |
| Basic EPS | -2.19 | -3.79 | -10.01 | -6.50 | — | +42.2% |
| Diluted EPS | -2.19 | -3.79 | -10.01 | -6.50 | — | +42.2% |
| EBIT | -$7.54M | -$12.01M | -$29.30M | -$16.24M | — | +37.3% |
| EBITDA | -$7.43M | -$11.78M | -$28.96M | -$15.68M | — | +36.9% |
| Basic shares | 2.79M | 2.79M | 2.71M | 2.31M | — | +0.0% |
| Diluted shares | 2.79M | 2.79M | 2.71M | 2.31M | — | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $11.03M | $19.49M | $7.51M | $12.45M | -43.4% |
| Cash & short-term investments | $24.00M | $23.93M | $38.00M | $33.63M | +0.3% |
| Accounts receivable | $1.97M | $3.60M | $377.00K | $62.00K | -45.3% |
| Total current assets | $26.97M | $31.30M | $41.17M | $43.05M | -13.8% |
| Property, plant & equipment | $1.17M | $1.63M | $2.15M | $1.54M | -28.3% |
| Total assets | $29.92M | $35.85M | $45.29M | $46.63M | -16.5% |
| Total current liabilities | $6.17M | $5.29M | $4.52M | $3.33M | +16.8% |
| Total debt | $991.00K | $1.31M | $1.65M | $772.00K | -24.2% |
| Total liabilities | $7.11M | $7.00M | $6.64M | $4.42M | +1.6% |
| Retained earnings | -$237.01M | -$230.88M | -$220.30M | -$193.06M | -2.7% |
| Shareholder equity | $22.81M | $28.85M | $38.64M | $42.21M | -20.9% |
| Working capital | $20.80M | $26.01M | $36.65M | $39.73M | -20.0% |
| Net tangible assets | $22.81M | $28.85M | $38.64M | $42.21M | -20.9% |
| Shares issued | 2.79M | 2.79M | 2.79M | 2.31M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$6.13M | -$10.58M | -$27.24M | -$14.92M | +42.1% |
| Depreciation & amortisation | $109.00K | $233.00K | $342.00K | $562.00K | -53.2% |
| Stock-based compensation | $82.00K | $786.00K | $1.86M | $1.53M | -89.6% |
| Change in working capital | $6.19M | -$4.40M | $7.67M | $3.54M | +240.7% |
| Operating cash flow | $322.00K | -$13.89M | -$17.73M | -$9.48M | +102.3% |
| Capital expenditure | -$47.00K | -$2.00K | -$134.00K | -$171.00K | -2,250.0% |
| Investing cash flow | -$8.58M | $26.69M | -$9.74M | $1.70M | -132.1% |
| Financing cash flow | $6.00K | $0 | $21.81M | $15.00K | — |
| Free cash flow | $275.00K | -$13.89M | -$17.86M | -$9.65M | +102.0% |
| End cash position | $12.22M | $20.66M | $7.86M | $13.60M | -40.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $108.00K | $696.00K | $400.00K | $17.26M | $1.03M | -84.5% |
| Operating revenue | $108.00K | $696.00K | $400.00K | $17.26M | $1.03M | -84.5% |
| Research & development | $2.79M | $3.58M | $5.73M | $4.65M | $8.84M | -22.3% |
| Selling, general & admin | $1.18M | $577.00K | $957.00K | $1.39M | $1.26M | +104.0% |
| Total operating expense | $3.96M | $4.11M | $6.69M | $6.03M | $10.10M | -3.5% |
| Operating income | -$3.85M | -$3.41M | -$6.29M | $11.23M | -$9.07M | -13.0% |
| Net interest income | $128.00K | $424.00K | $346.00K | $380.00K | $261.00K | -69.8% |
| Pre-tax income | -$3.73M | -$2.99M | -$5.94M | $11.61M | -$8.81M | -24.8% |
| Net income | -$3.73M | -$2.99M | -$5.94M | $11.61M | -$8.81M | -24.8% |
| Net income to common | -$3.73M | -$2.99M | -$5.94M | $11.61M | -$8.81M | -24.8% |
| Basic EPS | -1.31 | — | -2.13 | 4.17 | -3.20 | — |
| Diluted EPS | -1.31 | — | -2.13 | 4.17 | -3.20 | — |
| EBIT | -$3.85M | -$3.41M | -$6.29M | $11.23M | -$9.07M | -13.0% |
| EBITDA | -$3.85M | -$3.41M | -$6.29M | $11.23M | -$9.07M | -13.0% |
| Basic shares | 2.84M | — | 2.79M | 2.79M | 2.79M | — |
| Diluted shares | 2.84M | — | 2.79M | 2.79M | 2.79M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.14M | $11.03M | $6.71M | $10.22M | $16.89M | -8.1% |
| Cash & short-term investments | $52.83M | $24.00M | $20.84M | $24.29M | $16.90M | +120.1% |
| Accounts receivable | $1.07M | $1.97M | $9.85M | $10.04M | $3.88M | -45.8% |
| Total current assets | $55.79M | $26.97M | $31.65M | $36.26M | $23.43M | +106.8% |
| Property, plant & equipment | $1.04M | $1.17M | $1.28M | $1.39M | $1.51M | -11.1% |
| Total assets | $58.55M | $29.92M | $34.59M | $39.31M | $27.06M | +95.7% |
| Total current liabilities | $6.31M | $6.17M | $6.15M | $4.96M | $4.57M | +2.3% |
| Total debt | $862.00K | $991.00K | $1.08M | $1.18M | $1.18M | -13.0% |
| Total liabilities | $7.14M | $7.11M | $8.56M | $7.42M | $6.89M | +0.5% |
| Retained earnings | -$240.74M | -$237.01M | -$234.02M | -$228.08M | -$239.69M | -1.6% |
| Shareholder equity | $51.41M | $22.81M | $26.03M | $31.88M | $20.17M | +125.4% |
| Working capital | $49.48M | $20.80M | $25.50M | $31.31M | $18.86M | +137.9% |
| Net tangible assets | $51.41M | $22.81M | $26.03M | $31.88M | $20.17M | +125.4% |
| Shares issued | 3.27M | 2.79M | 2.79M | 2.79M | 2.79M | +17.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.31 | -1.13 | +51.1% |
| Mar 2026 | -2.86 | -1.31 | +54.2% |
| Dec 2025 | 0.39 | -1.06 | -371.8% |
| Sep 2025 | -2.09 | -2.13 | -1.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -3.01 | 1 | $200.00K | -50.0% |
| Next quarter | -2.67 | 1 | $250.00K | -64.1% |
| Current year | -9.48 | 2 | $469.33K | -97.6% |
| Next year | -7.70 | 4 | $500.00K | +6.5% |
Analyst targets & ownership
Mean target$196.67
High target$285.00
Low target$110.00
Implied upside153.01%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders59.61%
Held by institutions41.47%
Institutions holding29
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 24, 26 | Mizuho | INITIATED | — | Outperform |
| Jan 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 22, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 27, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 19, 24 | Raymond James | DOWNGRADE | Strong Buy | Outperform |
| May 22, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 13, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 11, 23 | Raymond James | MAINTAINED | Strong Buy | Strong Buy |
| Jul 24, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Moving averages & technicals
SMA 10
80.00
-2.84% from price
SMA 20
82.12
-5.34% from price
SMA 50
78.48
-0.95% from price
SMA 100
76.00
+2.27% from price
SMA 200
67.40
+15.33% from price
EMA 12
80.50
-3.44% from price
EMA 26
80.62
-3.58% from price
EMA 50
79.18
-1.83% from price
RSI (14)
46.1
Neutral
MACD (12,26,9)
-0.12
Hist -0.89
ATR (14)
6.58
8.47% of price
Realised vol 30D
80.8%
Annualised
Bollinger upper
90.05
20, 2σ
Bollinger lower
74.19
20, 2σ
50 / 200 cross
Golden
78.48 vs 67.40
Trend bias
Above 200
+15.33%
Risk profile
Beta vs SPY
0.84
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
80.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.4%
Peak to trough
Max drawdown 5Y
-96.5%
Peak to trough
ATR 14
6.58
8.47% of price
Beta (reported)
—
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateMay 5, 2025
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-20
Corporate Changes & Voting Matters
6-K · 2026-05-28
Corporate Changes & Voting Matters
6-K · 2026-03-24
Periodic Financial Reports
20-F · 2026-03-19
Corporate Changes & Voting Matters
6-K · 2025-12-17
Corporate Changes & Voting Matters
6-K · 2025-11-20
Corporate Changes & Voting Matters
6-K · 2025-11-14
Corporate Changes & Voting Matters
6-K · 2025-09-25
Headlines
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
GlobeNewswire · 3d ago
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
Zacks · 9d ago
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 12d ago
Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates
Zacks · 20d ago
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
Zacks · 87d ago
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
GlobeNewswire · 87d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.